Is Nintedanib now FDA approved for treating Idiopathic Pulmonary Fibrosis in adults?
Nintedanib is a kinase inhibitor that the U.S. Food and Drug Administration approved for use in adults with idiopathic pulmonary fibrosis. This approval marked a significant change in treatment options for this condition, which historically had very limited therapies available.
What the research says
Nintedanib is indicated specifically for the treatment of adults with idiopathic pulmonary fibrosis 4. Clinical trials demonstrated that this drug retards the rate of progression of the disease, though it does not completely stop the disease from advancing 6. The drug works by targeting specific pathways involved in the wound-healing responses that drive fibrosis 7.
What to ask your doctor
- Is nintedanib appropriate for my specific type of interstitial lung disease?
- How does nintedanib compare to pirfenidone for slowing disease progression?
- What are the common side effects I should watch for while taking nintedanib?
- Are there any genetic factors that might affect how well nintedanib works for me?
This question is drawn from common patient questions about Pulmonology & Critical Care and answered using cited medical research. We do not provide individualized advice.